David A. Siegel Tenaya Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Tenaya Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 213,500 shares of TNYA stock, worth $290,360. This represents 0.0% of its overall portfolio holdings.
Number of Shares
213,500
Previous 167,800
27.23%
Holding current value
$290,360
Previous $102,000
219.61%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding TNYA
# of Institutions
97Shares Held
38.2MCall Options Held
313KPut Options Held
61.1K-
Column Group LLC San Francisco, CA9.4MShares$12.8 Million18.17% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.06MShares$6.89 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.5MShares$6.13 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.07MShares$5.54 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.68MShares$2.28 Million0.0% of portfolio
About Tenaya Therapeutics, Inc.
- Ticker TNYA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,364,700
- Market Cap $56.3M
- Description
- Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hyp...